Voyager Therapeutics to Present Data on Alzheimer's Disease Programs at CTAD 2026

Article summary

Voyager Therapeutics announced that its tau-targeted gene therapy VY1706 and anti-tau antibody VY7523 will be featured in poster presentations at the upcoming Clinical Trials on Alzheimer's Disease (CTAD) 2026 conference.